Danielle DettlingSenior Director, Pre-Clinical Pharmacology at Maverick Therapeutics
Danielle Dettling is Senior Director of Preclinical Pharmacology at Maverick Therapeutics, where she leads program selection for Maverick’s COBRA platform. Together with her team she develops strategies for pre-clinical characterization for IND-enabling studies on COBRA lead molecules, and validation through toxicology studies to support therapeutic development in the solid tumor arena. Currently this includes the 2 COBRA Clinical Leads MVC-101, MVC-280 and subsequent pre-clinical programs. Danielle joined Maverick shortly after the company’s formation in 2017, and has over 10 years experience in the biotechnology and pharmaceutical industry, with specific expertise in novel biologic therapeutics for hematological and solid tumor indications, as well as therapeutics outside of the Oncology space. Prior to joining Maverick, Danielle was program lead for CD3 bispecific and CAR-T programs targeting hematological malignancies at the Pfizer Rinat site in San Francisco, and was additionally involved in computational assessment of optimal therapeutic targeting for many therapeutic antibody programs.